<scp>PIONEER REAL</scp> Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia
This real-world population of adults with T2D in Saudi Arabia experienced clinically significant reductions in HbA1c and BW, increased treatment satisfaction and a favourable safety profile, consistent with previously published PIONEER REAL studies.
Authors
- Mahmoud Ismail (ORCID: https://orcid.org/0000-0002-3164-6969)
- Mohamed Hassan Hatahet
- Hussein ElBadawi (ORCID: https://orcid.org/0009-0009-5974-7970)
- Mohammed Almehthel (ORCID: https://orcid.org/0000-0002-4031-881X)
- Stine H. Scheuer (ORCID: https://orcid.org/0000-0002-1244-9871)
- Nader Albalkhi
- Christina Louise Rasmussen (ORCID: https://orcid.org/0000-0003-3920-373X)
- Ahmed Elhadi Elsadig
- Dimitrios Baltzis (ORCID: https://orcid.org/0000-0002-4850-4633)
- Said Khader
- Ahmed Shalaby
- Ibrahim Al Kadhim
Institutions
- Riyadh Armed Forces Hospital (SA)
- University of British Columbia (CA)
- Wayne State University (US)
- Novo Nordisk (Denmark) (DK)
- Saad Specialist Hospital (SA)
- King Fahd Medical City (SA)
- Saudi Heart Association (SA)
- Children's Specialized Hospital (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1111/dom.70317
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk